- Prostatectomy is the surgery to remove cancer from prostate gland
- Observational treatment is keeping surveillance of disease and intervene timely
- Study reveals higher frequency of adverse health conditions after surgery
- Observational treatment can be adopted in low-risk cases
Followed by the study on mortality rate after prostatectomy and observation treatment in men with prostate cancer, the same team extended the research on after-surgery health.
The study revealed that surgery increased the chances of adverse events while observation treatment resulted in less health risks.
Prostatectomy is the surgery to remove the cancer cells from prostate gland which is present in the male reproductive system while observation treatment is the watchful intervention on the disease.
A team of scholars under a clinical trial named PIVOT studied the health condition and mortality of people who underwent prostate gland surgery for cancer during November 1994 to January 2002.
The research included 731 men with localized prostate cancer.
As many as 364 patients underwent surgery while 367 were assigned to observational treatment. Of the 364 who underwent surgery, 223 people (61.3 %) died while 245 died (66.8 %) in the observation group. During the years of study, urinary incontinence and erectile and sexual dysfunction were greater in patients who underwent surgery compared to the observation group.
Meanwhile, treatment of disease progression or spread of illness was less in those who underwent surgery. Limitations to do daily activities or disease related inconveniences were higher in patients who underwent surgery.
According to the researchers, the trial can help the patient and family to decide on treatment method and its adverse effects. But, in high-risk cancers, leaving it untreated may become lethal. Such cases need effective treatment as they are at greater risk for death.
The study also throws light upon the need for screening for prostate cancer. If the screening finds out low-risk condition of the disease, then they could continue on a surveillance program while intermediate or high-risk disease should get timely treatment options.
Prostate cancers are generally slow-growing and devoid of any symptoms in the beginning. Over 90 percent of prostate cancer appears in men above 50 years of age, and it is the second most common type of cancer in men.